MedTrace Logo

Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates

NCT03296059 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-25

No results posted yet for this study

Summary

Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017.

The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.

Conditions

  • Red Blood Cells(RBC)
  • Acute Respiratory Distress Syndrome (ARDS)

Interventions

OTHER

conventional treatment with RBC transfusion

Besides conventional treatment, neonates is given RBC transfusion.

OTHER

conventional treatment

neonates is treated with conventional treatment.

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Shi Yuan, PhD,MD · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Minutes
Max Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296059 on ClinicalTrials.gov